Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$16.72 USD

16.72
8,326,440

+0.18 (1.09%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $16.72 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of +10.71% and +2.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?

by Zacks Equity Research

VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.

Zacks Equity Research

VTRS Down on Late-Stage Study Failure of Eye Disease Drug

by Zacks Equity Research

VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.

Zacks Equity Research

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

by Zacks Equity Research

SDZNY, TEVA, and VTRS show resilience with strong biosimilar pipelines and margin strategies amid industry headwinds.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

by Sundeep Ganoria

Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.

Zacks Equity Research

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

by Zacks Equity Research

Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.

Zacks Equity Research

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.

Zacks Equity Research

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

by Zacks Equity Research

VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.

Zacks Equity Research

Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.